Lack of pharmacokinetic interaction between cholestyramine and acipimox, a new lipid lowering drug.
- 1 October 1986
- journal article
- clinical trial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 22 (4) , 496-497
- https://doi.org/10.1111/j.1365-2125.1986.tb02926.x
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Effects of Acipimox, a Nicotinic Acid Derivative, on Lipolysis in Human Adipose Tissue and on Cholesterol Synthesis in Human Jejunal MucosaClinical Science, 1985
- Radioimmunoassay of acipimox in human plasma and urinePharmacological Research Communications, 1984
- Reduced triglyceridemia and increased high density lipoprotein cholesterol levels after treatment with acipimox, anew inhibitor of lipolysisAtherosclerosis, 1981
- COLESTIPOL PLUS NICOTINIC ACID IN TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIAThe Lancet, 1981
- COLESTIPOL PLUS NICOTINIC-ACID IN TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA1981
- Lack of pharmacokinetic interaction of colestipol and fenofibrate in volunteersEuropean Journal of Clinical Pharmacology, 1980
- The Effect of Colestipol Hydrochloride on the Bioavailability and Pharmacokinetics of ClofibrateThe Journal of Clinical Pharmacology, 1979
- The Interaction Between Cholestyramine and DrugsExperimental Biology and Medicine, 1965